在中枢神经系统疾病中NMDAR的未来前景
Toni Capó1,2,3, Joan Biel Rebassa1,2,3, Iu Raïch1,2,3
1Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
Molecules (Basel, Switzerland)
|February 26, 2025
概括
甲基D-酸盐 (N-methyl-D-aspartate,NMDA) 受体是阿尔茨海默氏症和帕金森氏症等神经退行性疾病的潜在治疗点. 研究探讨了它在中枢神经系统疾病和未来治疗开发中的作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病 (阿尔茨海默氏症,帕金森氏症),中风和精神分裂症导致全球严重的残疾.
- 这些疾病影响着全世界数以百万计的人,目前还没有有效的治疗方法.
- N-甲基-D-酸盐 (NMDA) 受体 (NMDAR) 与学习,记忆和兴奋毒性有关.
研究的目的:
- 审查NMDARs在主要中枢神经系统 (CNS) 病理中的作用.
- 评估NMDARs作为这些疾病的潜在治疗点.
- 讨论以NMDAR为中心的治疗方法的未来前景.
主要方法:
- 对NMDAR功能和参与中枢神经系统疾病的文献综述.
- 对针对NMDARs的现有和潜在治疗策略的分析.
主要成果:
- 在神经退行性疾病和中风的病理生理学中,NMDARs起着至关重要的作用.
- 对NMDARs的失调与精神分裂症等疾病有关.
- 一些针对NMDAR的药物已经用于中枢神经系统疾病的症状管理.
结论:
- 对于开发用于治疗中枢神经系统衰弱性疾病的新型药理疗法,NMDARs是一个有前途的目标.
- 对NMDAR调制的进一步研究可能会导致对阿尔茨海默病,帕金森病,中风和精神分裂症的有效治疗方法.
相关概念视频
Long-term Depression
30.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
30.5K
Antiepileptic Drugs: Glutamate Antagonists
268
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
268
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
94
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
94
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Long-term Potentiation
2.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.7K
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422


